Back to News
investment

Why Paysign Stock Is Skyrocketing Today

newsfeedback@fool.com (Keith Noonan)
Loading...
3 min read
0 likes
Gemini_Generated_Image_h5l2xxh5l2xxh5l2 (1).png
Quantum News · Media Library

By Keith Noonan – Mar 25, 2026 at 2:20PM ESTKey PointsPaysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations. The company's forward guidance is spurring huge gains for the stock. Paysign (PAYS +36.87%) stock is surging higher in Wednesday's trading. The healthcare fintech services company's share price was up 35.8% as of 2:20 p.m. ET. At the same point in the daily session, the S&P 500 was up 0.7% and the Nasdaq Composite was up 0.9%. Paysign is likely getting a boost from bullish momentum for the broader market today, but the company's recent earnings report is the real catalyst behind today's explosive gains. On the other hand, the stock is still down roughly 1% across 2026's trading despite today's rally. Image source: Getty Images. Paysign posts Q4 sales beat Paysign published its fourth-quarter results after the market closed yesterday and reported sales that topped Wall Street's expectations. The company posted sales of $22.76 million in the period, beating the average analyst estimate's target for sales of $21.55 million. Meanwhile, earnings of $0.02 per share came in line with Wall Street's forecast. Revenue for the period was up nearly 26% year over year, and management's forward guidance suggests that strong sales momentum is poised to continue through this year. ExpandNASDAQ: PAYSPaysignToday's Change(36.87%) $1.39Current Price$5.16Key Data PointsMarket Cap$208MDay's Range$4.29 - $5.2152wk Range$1.80 - $8.88Volume136KAvg Vol391KGross Margin49.39% The market thinks Paysign's forward guidance is a gamechanger For 2026, Paysign expects its sales to be between $106.5 million and $110.5 million, with momentum in both its pharmaceuticals and plasma verticals seen as equal contributors to the expansion. Hitting the midpoint of that guidance range would mean posting annual revenue growth of approximately 32.5%. Meanwhile. net income is projected to come in between $13 million and $16 million -- up from $7.55 million last year. In addition to strong sales growth ,the projected earnings jump is being supported by expansion for gross margins. With management delivering a stronger-than-expected sales outlook and margins on an upward trend, the market could continue to reward Paysign. Read NextMar 25, 2026 •By Motley Fool TranscribingPaysign (PAYS) Q4 2025 Earnings Call TranscriptMar 25, 2026 •By Keithen DruryPrediction: Micron Will Be One of the Best-Performing Stocks of 2026Mar 25, 2026 •By Keith NoonanWhy Velo3D Stock Is Plummeting TodayMar 25, 2026 •By Billy DubersteinWhy EchoStar Rallied TodayMar 25, 2026 •By Geoffrey SeilerArm Holdings Shares Jump, but It Won't Be the Only CPU WinnerAbout the AuthorKeith Noonan is a contributing writer at The Motley Fool covering technology, consumer goods, and other sectors. He holds a bachelor’s degree in English from Boston College.TMFNoonsStocks MentionedPaysignNASDAQ: PAYS$5.16(+36.87%)+$1.39S&P 500 IndexSNPINDEX: ^GSPC$6,598.58(+0.64%)+$42.21NASDAQ Composite IndexNASDAQINDEX: ^IXIC$21,947.71(+0.85%)+$185.82*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Read Original

Tags

drug-discovery

Source Information

Source: The Motley Fool

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.